Macrocyclic Chelating Agents for Stable Eu3+ Fluorescence
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing time-resolved fluorescence immunoassays face challenges due to the poor binding stability of Eu3+ ions with conventional open-loop and linear-chain chelating agents, leading to weak fluorescence signals and reduced detection sensitivity.
Innovation Solution
A labeling method using the novel bifunctional chelating agent 2-S-(4-aminobenzene)-1,4,7 triazacyclononane-1,4,7-triacetic acid (NOTA) or 2-S-(4-aminobenzene)-1,4,7,10 tetraazacyclononane-1,4,7,10-tetraacetic acid (DOTA), which forms a more stable complex with Eu3+ ions, enhancing the fluorescence signal intensity and detection sensitivity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional open-loop and linear-chain chelating agents (EDTA, DTPA) are used to label Eu3+ on antibody, then the labeling process is simple and easy to manufacture, but the binding stability of Eu3+ ion complex is poor, leading to weak fluorescence signal and reduced detection sensitivity
Solution Approach 1:
The patent applies composite materials by combining the NOTA or DOTA chelating agent structure with the antibody and Eu3+ ion to form a stable ternary complex. The macrocyclic chelating agent provides enhanced coordination geometry and binding affinity for Eu3+, creating a more stable fluorescent complex compared to conventional linear chelating agents.
Solution Approach 2:
The patent changes the chemical structure parameters of the chelating agent from open-loop linear chains (EDTA, DTPA) to closed-loop macrocyclic structures (NOTA, DOTA). This structural parameter change results in improved thermodynamic stability and kinetic inertness of the Eu3+ complex, thereby enhancing fluorescence signal stability.
2Illumination intensity
If conventional chelating agents are used, then the manufacturing process is simple, but the fluorescence signal intensity is weak due to poor binding stability
Solution Approach 1:
The patent uses composite materials by integrating the macrocyclic NOTA or DOTA chelating agent with Eu3+ ion and antibody to form a stable fluorescent conjugate. This composite structure enhances the fluorescence signal intensity through improved Eu3+ binding stability and reduced ion dissociation.
Solution Approach 2:
The patent changes the molecular structure parameters of the chelating agent to macrocyclic form, which increases the stability constant of the Eu3+ complex. This parameter change directly enhances the fluorescence signal intensity by preventing Eu3+ dissociation during the assay process.
3Measurement precision
If conventional chelating agents are used, then the assay procedure is simple, but the detection sensitivity is reduced due to weak fluorescence signal
Solution Approach 1:
The patent employs composite materials by forming a stable Eu3+-NOTA/DOTA-antibody conjugate that provides enhanced fluorescence signal for detection. This composite structure improves measurement precision and detection sensitivity through stable Eu3+ binding and consistent fluorescence emission.
Solution Approach 2:
The patent changes the chelating agent structure to macrocyclic NOTA or DOTA, which increases the stability constant and improves the signal-to-noise ratio of the fluorescence measurement. This parameter change enhances detection sensitivity by maintaining stable Eu3+ binding throughout the assay.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of NOTA or DOTA as chelating agents results in a more stable Eu3+-labeled antibody complex, leading to stronger fluorescence signals and higher detection sensitivity for time-resolved fluorescence immunoassays.
Implementation Method 1
one end thereof is bonded to lanthanide elements, and another end thereof is linked to a free amino group on an antibody (or antigen), thus preparing a lanthanide Eu3+-labeled antibody (or antigen)
Implementation Method 2
Time-resolved fluorescence immunoassay (TRFIA) is a kind of booming high-sensitivity detection means in recent years
Data Source
AI summary
The present invention provides a labeling method for improving signal intensity of time-resolved fluorescence; and the labeling method can be applied in the detection of olaquindox or gentamicin. The olaquindox antibody complex immunolabelled by time-resolved fluorescence prepared in the present invention has a more stable structure, stronger fluorescence signal, and higher detection sensitivity.